Business Context and Reporting Period
This Form 8-K Current Report was filed by Kalaris Therapeutics, Inc. (KLRS) on July 6, 2026, covering events occurring on July 3, 2026. The filing addresses changes to the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
- Resignation: Morana Jovan-Embiricos, Ph.D., resigned as a member of the Board of Directors and the Audit Committee, effective immediately on July 3, 2026. The resignation was not related to any disagreement with the Company regarding operations, policies, or practices.
- Election: Laurie Keating was elected to the Board of Directors and the Audit Committee, effective August 1, 2026. She will serve as a Class I director with a term expiring at the 2027 annual meeting.
Guidance, Outlook, and Compensation
The filing details the compensatory arrangements for the newly elected director, Ms. Keating, effective August 1, 2026:
- Equity Grant: An option to purchase 18,000 shares of common stock at fair market value, vesting in equal monthly installments over three years. Full acceleration applies in the event of a change in control.
- Cash Compensation: $40,000 annual cash compensation for Board service and an additional $7,500 for Audit Committee service.
- Other: Annual equity grants per policy and reimbursement for reasonable travel and out-of-pocket expenses.
- Indemnification: Ms. Keating will enter into the Company's standard indemnification agreement, potentially requiring the Company to cover legal expenses, judgments, fines, and settlements arising from her service.
The filing contains no financial guidance, outlook, or discussion of risks and contingencies beyond the standard indemnification obligations.
Investor Verification Checklist
- Verify the effective date of Ms. Keating's service (August 1, 2026) versus the resignation date of Dr. Jovan-Embiricos (July 3, 2026) to assess any interim governance gaps.
- Review the Company's non-employee director compensation policy to understand the terms of the "annual equity grants" mentioned for Ms. Keating.
- Confirm the fair market value of the stock on the Grant Date to calculate the exercise price of the 18,000 share option.
- Assess the potential financial impact of the indemnification agreement on the Company's future liabilities.